2026-05-04T00:30:43Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/271392026-01-13T01:16:53Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Solana, Jose Carlos author Moreno, Javier author Iborra, Salvador author Soto, Manuel author Requena, Jose M author 2022-04 The control of diseases caused by protozoan parasites is one of the United Nations' Sustainable Development Goals. In recent years much research effort has gone into developing a new generation of live attenuated vaccines (LAVs) against malaria, Chagas disease and leishmaniasis. However, there is a bottleneck related to their biosafety, production, and distribution that slows downs further development. The success of irradiated or genetically attenuated sporozoites against malaria, added to the first LAV against leishmaniasis to be evaluated in clinical trials, is indicative that the drawbacks of LAVs are gradually being overcome. However, whether persistence of LAVs is a prerequisite for sustained long-term immunity remains to be clarified, and the procedures necessary for clinical evaluation of vaccine candidates need to be standardized. Solana JC, Moreno J, Iborra S, Soto M, Requena JM. Live attenuated vaccines, a favorable strategy to provide long-term immunity against protozoan diseases. Trends Parasitol. 2022 Apr;38(4):316-334. doi: 10.1016/j.pt.2021.11.004. Epub 2021 Dec 9. PMID: 34896016. 10.1016/j.pt.2021.11.004 Trends in Parasitology 34896016 https://hdl.handle.net/20.500.12105/27139 Chagas disease Attenuated vaccines Genetically modified parasites Leishmaniasis Malaria Live attenuated vaccines, a favorable strategy to provide long-term immunity against protozoan diseases.